美国FDA 批准勃林格殷格翰慢阻肺新药能倍乐上市！

COPD, which includes chronic bronchitis and emphysema, is a serious but treatable lung disease. Respimat is a spray form of tiotropium bromide, used to treat adult COPD. It is produced and developed by Boehringer Ingelheim, Germany. In May 2015, the U.S. Food and Drug Administration (FDA) approved the marketing of once-daily Respimat inhalation spray.

The landmark TIOSPIRTM trial confirmed that Spirava Respimat 2.5 μg and Spirava Respimat (HandiHaler) 18 μg have similar safety and effectiveness. Both formulations of Spirava are in a leading position in the maintenance treatment of COPD. The time to the first acute exacerbation of COPD for the two formulations of Spirava (tiotropium bromide) is similar. To study the therapeutic effect of inhaled Respimat in the treatment of stable chronic obstructive pulmonary disease ODPD. Methods: 40 patients with stable COPD were randomly divided into 2 groups. The treatment group was given Respimat inhalation, and the control group was given conventional aminophylline 0.1g Tid and albuterol aerosol (used as needed). Compare the lung function and 6-minute walking distance between the two groups before and after treatment. Results: Compared with the control group, FEV1/FVC and the percentage of predicted FEV1 in the treatment group were significantly increased, and the 6-minute walking distance was significantly improved. Conclusion: Inhaled Respimat can effectively improve lung function.

In terms of safety, dry mouth is a common adverse reaction of Respimat. After taking Respimat, there may also be immediate allergic reactions, such as rash, urticaria, swelling of the mouth and face, sudden difficulty breathing (angioedema) or other allergic reactions (such as sudden drop in blood pressure or dizziness). If such a situation occurs, please consult a doctor immediately for symptomatic treatment.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: